The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Positive safety and efficacy data from 4 clinical studies supported the CE marking.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.

John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.